Furthermore, treatment with activated B cells inhibited the percentage of CD4+IL-17+ Th17 cells, decreased intracellular RORγt expression in CD4+ T cells of lupus mice spleens, and reduced serum IL-17. Here, IL17A is linked to systemic lupus erythematosus.